MSD
MSD teams up with Harvard to develop new leukaemia treatments
March 24, 2016Medical Communications, Research and Development AML, Harvard, MSD, leukaemia
MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …
Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute
March 23, 2016Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi
Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …
New manufacturing boss for MSD
March 10, 2016Manufacturing and Production, Medical Communications MSD, manufacturing
MSD has appointed Sanat Chattopadhyay president of the Merck Manufacturing Division (MMD) and an executive vice president of the company. …
MSD joins charity-industry partnership Dementia Consortium
March 9, 2016Medical Communications, Research and Development MSD, alzheimer's society, dementia, dementia consortium
The Dementia Consortium has welcomed MSD into the fold as a new partner in its global venture to accelerate drug …
Sanofi Pasteur and MSD end European vaccines partnership
March 8, 2016Medical Communications, Research and Development, Sales and Marketing MSD, Sanofi Pasteur, Sanofi pasteur msd, vaccines
Sanofi Pasteur and MSD have announced that they will end their joint vaccines operations in Europe, bringing an end to …
CHMP recommends Sanofi’s two-dose schedule HPV vaccine
March 3, 2016Research and Development HPV vaccine, MSD, Sanofi Pasteur
Sanofi Pasteur’s and MSD’s vaccine against human papillomavirus (HPV), Gardasil 9, has received a positive opinion from the European Medicine …
MHRA approves new indication for MSD’s Ezetrol
February 26, 2016Medical Communications, Research and Development, Sales and Marketing MHRA, MSD, NICE, ezetrol
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …
FDA approves Gilead’s Harvoni in two new indications
February 18, 2016Research and Development Gilead Sciences, MSD, harvoni, hepatitis C
The hepatitis C treatment battle had its latest development yesterday, with the FDA awarding Gilead Science’s market-leading drug Harvoni (ledipasvir/sofosbuvir) …
MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst
February 10, 2016Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C
The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …
Revenues down at MSD
February 4, 2016Sales and Marketing MSD, financial performance, profits, revenue, sales
MSD (Merck, Sharpe and Dohme) reported a mixed bag of financial figures today, as the company announced full-year 2015 revenues …
MSD gets FDA approval for hepatitis C drug Zepatier
January 29, 2016Medical Communications, Sales and Marketing FDA, MSD, Zepatier, hepatitis C
The competitive hepatitis C market is to get another contender, with FDA approving MSD’s new combo treatment Zepatier (elbasvir and …
MSD and GAVI agree Ebola vaccine deal
January 20, 2016Manufacturing and Production, Research and Development Ebola, GAVI, MSD, WHO
MSD and the global vaccine alliance Gavi have agreed a deal to provide 300,000 dosesof an Ebola virus vaccine, to …
MSD sues German Merck for using name in US
January 15, 2016Medical Communications, Sales and Marketing MSD, Merck
MSD says it is filing a lawsuit against the German company Merck “regarding their improper use of the name ‘Merck’ …
BioLineRx to test lead candidate with MSD’s Keytruda in pancreatic cancer
January 13, 2016Research and Development MSD, immunotherapy, keytruda, pembrolizumab
Israeli biopharma company BioLineRx has announced a collaboration with MSD on a Phase II study investigating its lead oncology candidate, …
MSD to acquire Scottish firm IOmet Pharma
January 12, 2016Research and Development, Sales and Marketing IOMet Pharma, MSD, Merck, Scotland, acquisitions, immuno-oncology, mergers, oncology
US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
